Current State of Drug Therapies for Antibody-mediated Rejection After Heart Transplantation
Canadian Journal of Cardiology · 2026-02 · 42 (2) · 346-355
DOI: 10.1016/j.cjca.2025.10.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Canadian Journal of Cardiology, 2026-02. Verfasst von Erik Henricksen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transplant, Stanford Health Care, Stanford, California, USA. Electronic address: henrice@stanford.edu. Hauptthemen laut MEDLINE: Graft Rejection, Heart Transplantation, Immunosuppressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 77 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Transplant, Stanford Health Care, Stanford, California, USA. Electronic address: henrice@stanford.edu.
- Department of Pharmacy, Michigan Medicine, Ann Arbor, Michigan, USA.
- Department of Pharmacy, University of California Irvine Health, Irvine, California, USA.
Zitieren
APA
Henricksen, E., Walter, K., & Lichvar, A. (2026). Current State of Drug Therapies for Antibody-mediated Rejection After Heart Transplantation. Canadian Journal of Cardiology, 42(2), 346-355. https://doi.org/10.1016/j.cjca.2025.10.005
Vancouver
Henricksen E, Walter K, Lichvar A. Current State of Drug Therapies for Antibody-mediated Rejection After Heart Transplantation. Canadian Journal of Cardiology. 2026;42(2):346-355. doi:10.1016/j.cjca.2025.10.005
BibTeX
@article{Henricksen2026,
author = {Henricksen, Erik and Walter, Krysta and Lichvar, Alicia},
title = {Current State of Drug Therapies for Antibody-mediated Rejection After Heart Transplantation},
journal = {Canadian Journal of Cardiology},
year = {2026},
volume = {42},
number = {2},
pages = {346--355},
doi = {10.1016/j.cjca.2025.10.005}
}
EUVIMED